What is pineoblastoma?
Pineoblastoma is a rare, fast-growing brain tumour that starts in the pineal gland. This small gland, deep in the centre of the brain, makes the hormone melatonin, which helps to control the sleep-wake cycle.
Pineoblastoma is an embryonal tumour, meaning it is made of immature cells that look like the cells of a developing embryo. The World Health Organization classifies it as grade 4, the most aggressive grade (Louis et al., 2021).
It mainly affects children, especially under the age of 10, but it can also occur in teenagers and adults. Because the pineal gland sits next to the channels that drain spinal fluid, pineoblastoma often causes hydrocephalus, a build-up of fluid and pressure in the brain.
Pineoblastoma can spread through the cerebrospinal fluid (CSF) to other parts of the brain and spine. Treatment usually combines surgery, chemotherapy and radiotherapy. The outlook is much better for older children than for very young ones (Mynarek et al., 2017).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of tumour | Embryonal tumour of the pineal gland, WHO grade 4 |
| How common | Very rare; under 1% of childhood brain tumours |
| Typical age | Mostly children, median about 5-8; also infants and adults |
| Main site | Pineal region, at the back of the third ventricle |
| Key symptoms | Headache, vomiting, problems looking upwards, double vision |
| Genetic links | DICER1 syndrome; RB1 (trilateral retinoblastoma) |
| Main treatment | Surgery, chemotherapy and radiotherapy to the brain and spine |
| Outlook | About 60-80% long-term survival in older children; poorer in infants |
2. Types and molecular groups
The pineal gland can give rise to several tumours. Pineoblastoma is the most aggressive of the pineal parenchymal tumours:
| Tumour | WHO grade | Behaviour |
|---|---|---|
| Pineocytoma | 1 | Slow-growing; usually adults; often cured by surgery |
| Pineal parenchymal tumour of intermediate differentiation | 2 or 3 | In between |
| Papillary tumour of the pineal region | 2 or 3 | Usually adults |
| Pineoblastoma | 4 | Fast-growing; usually children |
Research has shown that pineoblastoma itself includes four main molecular groups, which differ in age and outlook (Li et al., 2020; Liu et al., 2020):
| Molecular group | Typical age | Main gene changes | Outlook |
|---|---|---|---|
| PB-miRNA1 | Children | DICER1, DROSHA or DGCR8 changes | Intermediate |
| PB-miRNA2 | Older children | DICER1, DROSHA or DGCR8 changes | Better |
| PB-MYC/FOXR2 | Infants | MYC gain, FOXR2 activation | Poor |
| PB-RB1 | Infants | RB1 loss | Poor |
3. Causes and risk factors
Most pineoblastomas occur without a known cause. Some are linked with inherited conditions:
| Condition | Notes |
|---|---|
| DICER1 syndrome | An inherited change in DICER1; also linked with pleuropulmonary blastoma and other tumours (de Kock et al., 2014) |
| Hereditary retinoblastoma (RB1) | Children with inherited retinoblastoma can develop a pineoblastoma, known as trilateral retinoblastoma (de Jong et al., 2015) |
| Other rare gene changes | Being studied |
Children with pineoblastoma are therefore often offered genetic testing. Children with hereditary retinoblastoma have brain MRI checks in early childhood in some centres.
Pineoblastoma is not infectious, and it is not caused by anything parents did or did not do. No lifestyle, dietary or environmental cause has been found.
4. How does it look
On scans
MRI with contrast is the main test. It usually shows:
| Feature | Description |
|---|---|
| Location | A mass in the pineal region, behind the third ventricle |
| Size | Often larger than 3 cm at diagnosis |
| Appearance | Lobulated, partly solid, enhancing with contrast; may contain cysts or calcium |
| Hydrocephalus | Enlarged fluid spaces caused by blockage of the aqueduct |
| Spread | Coating of the brain or spinal cord surface, or nodules in the spine |
MRI of the whole spine is done to look for spread through the CSF, which is present in about a quarter to a third of patients at diagnosis.
Under the microscope
Pineoblastoma consists of densely packed small, round, blue cells with little cytoplasm and many dividing cells. Cells may form rosettes, small ring-shaped groups.
Staining for synaptophysin and other neuronal markers is usually positive. Doctors also check tumour markers to rule out germ cell tumours, which are another common cause of a pineal mass. A specialist neuropathologist usually reviews the sample, and DNA methylation testing is increasingly used to confirm the diagnosis.
Visible signs
The tumour itself is not visible, but pressure on nearby brain areas can cause signs that others notice:
| Sign | What it looks like |
|---|---|
| Parinaud syndrome | The eyes cannot look upwards; pupils react poorly to light |
| “Sunsetting” eyes | Eyes turned downwards, especially in babies |
| Enlarging head | In babies, from hydrocephalus |
| Unsteady walking | Clumsiness or poor balance |
| Drowsiness | From raised pressure in the head |
5. Symptoms
Raised pressure in the head
Most symptoms come from hydrocephalus:
- Headaches, often worse in the morning
- Nausea and vomiting, especially in the morning
- Tiredness and sleepiness
- Irritability and changes in behaviour
- Blurred vision from swelling at the back of the eyes (papilloedema)
Eye and movement symptoms
- Difficulty looking up (part of Parinaud syndrome)
- Double vision
- Jerky eye movements when trying to look up
- Unsteadiness and clumsiness
Babies and young children
- Rapidly growing head and bulging soft spot
- Vomiting and poor feeding
- Loss of developmental skills
Spread to the spine
- Back pain
- Weakness or numbness in the legs
- Bladder or bowel problems
When to seek medical advice
Seek urgent help for severe headache with vomiting, drowsiness, confusion or a seizure.
See a doctor promptly if a child has headaches that wake them up, repeated morning vomiting, double vision or difficulty looking upwards.
6. Diagnosis
| Test | Purpose |
|---|---|
| MRI of the brain and spine | Shows the tumour, hydrocephalus and any spread |
| Blood and CSF tumour markers (AFP, beta-hCG) | Help exclude germ cell tumours |
| CSF cytology | Looks for tumour cells in the spinal fluid |
| Surgery or biopsy | Confirms the diagnosis |
| DNA methylation profiling | Identifies the molecular group |
| Genetic testing | For DICER1, RB1 and other inherited changes |
| Eye examination | Checks for retinoblastoma and raised pressure |
Other tumours of the pineal region
Several different tumours can grow in the pineal region, and they are treated very differently. Getting the exact diagnosis is therefore essential:
| Tumour | Typical age | Key clue |
|---|---|---|
| Germinoma | Teenagers and young adults, mostly boys | Raised beta-hCG in some; very sensitive to radiotherapy |
| Non-germinomatous germ cell tumour | Children and teenagers | Raised AFP or beta-hCG in blood or CSF |
| Pineocytoma | Adults | Slow-growing; well-defined on MRI |
| Pineal cyst | Any age | Common, fluid-filled and harmless |
| Pineoblastoma | Mostly young children | Large, lobulated mass; normal tumour markers |
If tumour markers are clearly raised, a germ cell tumour can sometimes be diagnosed without surgery. When markers are normal, a biopsy is needed.
Risk groups
Doctors divide patients into risk groups to guide treatment (Liu et al., 2020):
| Risk group | Features |
|---|---|
| Standard risk | Age over 3, no spread, little tumour left after surgery |
| High risk | Spread through the CSF or significant tumour remaining |
| Young children | Under 3; treatment avoids or delays radiotherapy |
7. Treatment
Pineoblastoma is treated at a specialist paediatric neuro-oncology centre.
Treating hydrocephalus
The first step is often to relieve pressure in the head. This may be done with an endoscopic third ventriculostomy (ETV), a small opening that lets CSF bypass the blockage, or with a shunt. A biopsy and CSF sample can often be taken during the same procedure.
Surgery
Surgeons try to remove as much tumour as safely possible. The pineal region lies deep among important veins and brain structures, so complete removal is not always possible. Surgery may cause temporary eye movement problems, which often improve.
Recovery after surgery
Most children spend a short time in intensive care after the operation, then several days on the ward. Some have temporary problems with eye movements, balance, speech or alertness, which often improve over weeks.
Physiotherapists, occupational therapists and speech therapists help with recovery. Radiotherapy and chemotherapy usually begin within a few weeks of surgery.
Radiotherapy
| Age group | Radiotherapy |
|---|---|
| Older children and adults | Craniospinal radiotherapy to the whole brain and spine, with a higher dose to the tumour area |
| Children under about 3 | Usually avoided or delayed because of its effects on the developing brain |
Chemotherapy
| Situation | Chemotherapy |
|---|---|
| With and after radiotherapy | Combinations such as cisplatin, cyclophosphamide and vincristine, similar to medulloblastoma treatment |
| Young children | Intensive chemotherapy, sometimes high-dose chemotherapy with stem cell rescue, to delay or avoid radiotherapy |
| Relapse | Further chemotherapy, radiotherapy or clinical trials |
Side effects
| Side effect | Notes |
|---|---|
| Low blood counts and infections | During chemotherapy |
| Hearing loss | From cisplatin |
| Tiredness | During and after radiotherapy |
| Hair loss | Usually temporary |
| Sickness | Controlled with anti-sickness medicines |
8. Outlook (prognosis)
The outlook depends strongly on age, spread and molecular group (Tate et al., 2012; Mynarek et al., 2017; Liu et al., 2020):
| Group | Approximate long-term survival |
|---|---|
| Older children, no spread | About 70-80% or more |
| Older children with spread | About 40-60% |
| Children under 3 | Much lower, often under 30-40% |
| PB-miRNA2 group | Best outcomes |
| PB-MYC/FOXR2 and PB-RB1 groups | Poorest outcomes |
Why molecular testing matters
Two children with pineoblastomas that look the same under the microscope can have very different outlooks. Molecular testing helps doctors to identify children who may do well with standard treatment and those who might benefit from more intensive treatment or a clinical trial.
In the future, molecular groups are expected to guide treatment more directly, as they already do for medulloblastoma.
9. Long-term effects and follow-up
Children are followed up with regular MRI scans of the brain and spine for many years. Survivors may need support for late effects:
| Late effect | Support |
|---|---|
| Learning and memory | School support and neuropsychology assessment |
| Growth and puberty | Hormone tests and treatment by an endocrinologist |
| Hearing | Hearing aids if needed |
| Thyroid function | Regular blood tests after spinal radiotherapy |
| Eye movement and vision | Eye clinic follow-up |
| Second tumours | Particularly in DICER1 or RB1 carriers |
10. Living with pineoblastoma
- Ask for a named key worker to coordinate care
- Work with the school on learning support and time off
- Seek emotional support for the whole family, including brothers and sisters
- Ask about genetic counselling for the family
- Keep a record of treatment details for future follow-up
- Ask about melatonin or sleep support if sleep patterns change after treatment
- Plan breaks and rest, as tiredness can last for months after radiotherapy
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is pineoblastoma the same as a pineal cyst? | No. Pineal cysts are common and harmless; pineoblastoma is a malignant tumour |
| Will my child need radiotherapy? | Older children usually do; very young children may have chemotherapy instead |
| Is it inherited? | Usually not, but some cases are linked with DICER1 or RB1 changes |
| Will the eye problems get better? | Often they improve after pressure is relieved and treatment begins |
| Can adults get pineoblastoma? | Yes, but rarely |
| What is proton beam therapy? | A type of radiotherapy that can reduce the dose to healthy brain tissue; it is often used for children |
| Can the tumour come back? | Yes, most relapses happen in the first few years, which is why regular scans are needed |
12. Questions to ask your care team
- What molecular group is the tumour?
- Has the tumour spread to the spine?
- How much of the tumour was removed?
- What treatment plan do you recommend for my child’s age?
- Should we have genetic testing?
- What late effects should we look out for?
- Is proton beam therapy an option?
- Are there clinical trials suitable for my child?
- Who should we call if symptoms such as headache or vomiting return?
Resources
- Louis, D.N. et al. (2021) ‘The 2021 WHO Classification of Tumors of the Central Nervous System: a summary’, Neuro-Oncology, 23(8), pp. 1231-1251.
- Li, B.K. et al. (2020) ‘Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study’, Acta Neuropathologica, 139(2), pp. 223-241.
- Liu, A.P.Y. et al. (2020) ‘Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials’, Acta Neuropathologica, 139(2), pp. 259-271.
- Mynarek, M. et al. (2017) ‘Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data’, Neuro-Oncology, 19(4), pp. 576-585.
- Tate, M. et al. (2012) ‘The long-term postsurgical prognosis of patients with pineoblastoma’, Cancer, 118(1), pp. 173-179.
- de Kock, L. et al. (2014) ‘Germ-line and somatic DICER1 mutations in pineoblastoma’, Acta Neuropathologica, 128(4), pp. 583-595.
- de Jong, M.C. et al. (2015) ‘The incidence of trilateral retinoblastoma: a systematic review and meta-analysis’, American Journal of Ophthalmology, 160(6), pp. 1116-1126.
- Snuderl, M. et al. (2018) ‘Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma’, Nature Communications, 9(1), p. 2868.
- National Cancer Institute (2026) Childhood Central Nervous System Embryonal Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.